[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Arrowhead Pharma (ARWR)

Arrowhead Pharma (ARWR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,960,168
  • Shares Outstanding, K 140,857
  • Annual Sales, $ 829,450 K
  • Annual Income, $ -1,630 K
  • EBIT $ -226 M
  • EBITDA $ -208 M
  • 60-Month Beta 1.27
  • Price/Sales 15.04
  • Price/Cash Flow 741.96
  • Price/Book 26.78

Options Overview Details

View History
  • Implied Volatility 54.78% (+4.44%)
  • Historical Volatility 60.20%
  • IV Percentile 8%
  • IV Rank 16.01%
  • IV High 94.92% on 11/17/25
  • IV Low 47.13% on 08/13/26
  • Expected Move (DTE 18) 5.78 (7.10%)
  • Put/Call Vol Ratio 0.07
  • Today's Volume 1,530
  • Volume Avg (30-Day) 1,412
  • Put/Call OI Ratio 0.53
  • Today's Open Interest 42,753
  • Open Int (30-Day) 46,076
  • Expected Range 75.58 to 87.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-1.59
  • Number of Estimates 9
  • High Estimate $-0.35
  • Low Estimate $-3.00
  • Prior Year $-0.18
  • Growth Rate Est. (year over year) -783.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
80.75 +1.11%
on 08/31/26
90.97 -10.25%
on 08/11/26
-3.00 (-3.54%)
since 07/31/26
3-Month
69.30 +17.82%
on 06/02/26
95.49 -14.49%
on 07/22/26
+3.74 (+4.80%)
since 05/29/26
52-Week
21.61 +277.83%
on 08/29/25
95.49 -14.49%
on 07/22/26
+59.31 (+265.49%)
since 08/28/25

Most Recent Stories

More News
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia

- Plozasiran reduced triglycerides (TG) by 79% and 81% versus placebo in SHASTA-3 and SHASTA-4 across the broad sHTG population - - More than 90% of plozasiran-treated patients achieved triglycerides...

ARWR : 81.58 (-3.92%)
Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress

- Detailed results from the Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia will be presented as a HOT LINE Late-Breaking Science Session on August 30,...

ARWR : 81.58 (-3.92%)
People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides

REDEMPLO® (plozasiran) is listed in the Lauer-Taxe® database as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS), diagnosed either based...

ARWR : 81.58 (-3.92%)
Arrowhead Research: Fiscal Q3 Earnings Snapshot

Arrowhead Research: Fiscal Q3 Earnings Snapshot

ARWR : 81.58 (-3.92%)
Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results

- Conference Call and Webcast Today, August 4, 2026, at 4:30 p.m. ET

ARWR : 81.58 (-3.92%)
Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher

- Voucher to be used to accelerate review of a planned sNDA for plozasiran in severe hypertriglyceridemia

ARWR : 81.58 (-3.92%)
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 16, 2026, the Company’s Board of Directors approved...

ARWR : 81.58 (-3.92%)
Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

- Study completion anticipated in mid-2027

ARWR : 81.58 (-3.92%)
Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia

Deep, durable, and consistent median triglyceride reductions of 79% and 81% from baseline in SHASTA-3 and SHASTA-4, respectively Statistically significant reduction in acute pancreatitis...

ARWR : 81.58 (-3.92%)
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 4, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal...

ARWR : 81.58 (-3.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes....

See More

Key Turning Points

3rd Resistance Point 91.42
2nd Resistance Point 89.83
1st Resistance Point 87.37
Last Price 81.58
1st Support Level 83.32
2nd Support Level 81.73
3rd Support Level 79.27

See More

52-Week High 95.49
Last Price 81.58
Fibonacci 61.8% 67.27
Fibonacci 50% 58.55
Fibonacci 38.2% 49.83
52-Week Low 21.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.